Halipa, Jaharia .

HRN: 18-69-41  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/02/2025
CEFAZOLIN 1GM (VIAL)
12/02/2025
12/02/2025
IV
2grams
PTOR
Stat CS
Waiting Final Action 
12/02/2025
CEFUROXIME 500MG (TAB)
12/02/2025
12/09/2025
PO
1 Tab
BID
S/P CS
Checking Initial Appropriateness 
12/02/2025
MUPIROCIN 2%, 15G (TUBE)
12/02/2025
12/09/2025
TOPICAL
Pea Size
BID
S/P CS
Checking Initial Appropriateness 
12/03/2025
CEFUROXIME 1.5GM (VIAL)
12/03/2025
12/10/2025
IV
1.5g LD Then 750
Q8
Ltcs
Checking Final Appropriateness 
12/04/2025
CEFUROXIME 1.5GM (VIAL)
12/04/2025
12/05/2025
IVT
1.5gms
Q8
LTCS
Checking Final Appropriateness 
12/05/2025
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
12/05/2025
12/12/2025
IV
4.5g
Q6
S/P Repeat LTCS; T/c Sepsis
Checking Initial Appropriateness 
12/09/2025
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
12/09/2025
12/16/2025
IV
500mg
Q8
S/p Cs
Checking Final Appropriateness 
12/09/2025
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
12/09/2025
12/16/2025
IV
4.5g
Q6
Tc Sepsis
Checking Final Appropriateness 
12/14/2025
COTRIMOXAZOLE 960MG (TAB)
12/14/2025
12/20/2025
PO
960mg
Q12
T/C Catheter Associated UTI
Checking Final Appropriateness 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: